Interleukin (IL)-17A is a key proinflammatory cytokine indicated in multiple pathologies, including skin tumorigenesis. While IL-17A is a signature cytokine of Th17 cells, IL-17A is also produced by other cell types, including type 3 innate lymphoid cells (ILC3s) in the skin, particularly in patients with psoriasis. Interestingly, we detect CD45+Lin−(CD3−CD14−CD19−CD20−) IL-17A+ cells in the cutaneous squamous cell carcinomas (cSCCs) by flow cytometry of the cell suspensions prepared from tumor tissues. Consistently, we found CD3−IL-17+ cells in tumor tissue of skin cSCCs by immunohistochemistry staining of serial sections of SCCs from both immunocompetent and immunocompromised patients (e.g., transplant patients on iatrogenic long-term immunosuppressive therapy). In several immunocompromised patients, the CD3−IL-17+ cells consist of over 90% of the total IL-17+ cells in the tumor tissue. Furthermore, these CD3−IL-17+ cells are negatively stained for SMA, CD11b, and CD19, suggesting that they are unlikely to be fibroblast, myeloid cells, or B cells. Taken together, we found a population of lineage-negative IL-17A-producing cells present in the cSCCs, which share the “CD45+Lin−” features with ILCs. This study suggests that IL-17A can be produced by immune cell populations other than T cells in skin SCCs.
Bata-CsörgöZ, SzellM. 2012. The psoriatic keratinocytes. Expert Rev Dermatol, 7(5):473–481.
3.
BlauveltA, ReichK, TsaiT-F, TyringS, VanaclochaF, KingoK, ZivM, PinterA, VenderR, HugotS. 2017. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol, 76(1):60–69. e9.
4.
BrinL, ZubairAS, BrewerJD. 2014. Optimal management of skin cancer in immunosuppressed patients. Am J Clin Dermatol, 15(4):339–356.
CellaM, OteroK, ColonnaM. 2010. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci U S A, 107(24):10961–10966.
HamadaH, Garcia-Hernandez MdeL, ReomeJB, MisraSK, StruttTM, McKinstryKK, CooperAM, SwainSL, DuttonRW. 2009. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol, 182(6):3469–3481.
12.
HarringtonLE, HattonRD, ManganPR, TurnerH, MurphyTL, MurphyKM, WeaverCT. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6(11):1123–1132.
13.
HeD, LiH, YusufN, ElmetsCA, AtharM, KatiyarSK, XuH. 2012. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS One, 7(2):e32126.
14.
HussainSK, SundquistJ, HemminkiK. 2010. Incidence trends of squamous cell and rare skin cancers in the Swedish national cancer registry point to calendar year and age-dependent increases. J Invest Dermatol, 130(5):1323–1328.
15.
KuangD-M, PengC, ZhaoQ, WuY, ZhuL-Y, WangJ, YinX-Y, LiL, ZhengL. 2010. Tumor-activated monocytes promote expansion of IL-17–producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol, 185(3):1544–1549.
16.
LamJKS, SundaresanP, GebskiV, VenessMJ. 2018. Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: poor outcome unrelated to the index lesion. Head Neck, 40(5):985–992.
17.
LangleyRG, ElewskiBE, LebwohlM, ReichK, GriffithsCE, PappK, PuigL, NakagawaH, SpelmanL, SigurgeirssonB. 2014. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med, 371(4):326–338.
18.
LangrishCL, ChenY, BlumenscheinWM, MattsonJ, BashamB, SedgwickJD, McClanahanT, KasteleinRA, CuaDJ. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med, 201(2):233–240.
19.
LiX, BecharaR, ZhaoJ, McGeachyMJ, GaffenSL. 2019. IL-17 receptor-based signaling and implications for disease. Nat Immunol, 20(12):1594–1602.
20.
LoBC, Canals HernaezD, ScottRW, HughesMR, ShinSB, UnderhillTM, TakeiF, McNagnyKM. 2019. The transcription factor RORalpha preserves ILC3 lineage identity and function during chronic intestinal infection. J Immunol, 203(12):3209–3215.
MaggioniD, PignataroL, GaravelloW. 2017. T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma. Oncoimmunology, 6(7):e1325066.
23.
ManyamBV, GarsaAA, ChinRI, ReddyCA, GastmanB, ThorstadW, YomSS, NussenbaumB, WangSJ, VidimosAT, KoyfmanSA. 2017. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer, 123(11):2054–2060.
24.
McGeachyMJ, CuaDJ, GaffenSL. 2019. The IL-17 family of cytokines in health and disease. Immunity, 50(4):892–906.
25.
MontaldoE, Teixeira-AlvesLG, GlatzerT, DurekP, StervboU, HamannW, BabicM, PaclikD, StolzelK, GroneJ, LozzaL, JuelkeK, MatzmohrN, LoiaconoF, PetronelliF, HuntingtonND, MorettaL, MingariMC, RomagnaniC. 2014. Human RORgammat(+)CD34(+) cells are lineage-specified progenitors of group 3 RORgammat(+) innate lymphoid cells. Immunity, 41(6):988–1000.
26.
NardinocchiL, SonegoG, PassarelliF, AvitabileS, ScarponiC, FaillaCM, SimoniS, AlbanesiC, CavaniA. 2015. Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol, 45(3):922–931.
27.
NumasakiM, WatanabeM, SuzukiT, TakahashiH, NakamuraA, McAllisterF, HishinumaT, GotoJ, LotzeMT, KollsJK, SasakiH. 2005. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol, 175(9):6177–6189.
28.
PapottoPH, RibotJC, Silva-SantosB. 2017. IL-17(+) gammadelta T cells as kick-starters of inflammation. Nat Immunol, 18(6):604–611.
29.
PuntS, DronkersEA, WeltersMJ, GoedemansR, KoljenovicS, BloemenaE, SnijdersPJ, GorterA, van der BurgSH, Baatenburg de JongRJ, JordanovaES. 2016. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol Immunother, 65(4):393–403.
30.
PuntS, LangenhoffJM, PutterH, FleurenGJ, GorterA, JordanovaES. 2015. The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology, 4(2):e984547.
31.
RaykovaA, CarregaP, LehmannFM, IvanekR, LandtwingV, QuastI, LunemannJD, FinkeD, FerlazzoG, ChijiokeO, MunzC. 2017. Interleukins 12 and 15 induce cytotoxicity and early NK-cell differentiation in type 3 innate lymphoid cells. Blood Adv, 1(27):2679–2691.
32.
RenouxVM, ZriwilA, PeitzschC, MichaelssonJ, FribergD, SonejiS, SitnickaE. 2015. Identification of a human natural killer cell lineage-restricted progenitor in fetal and adult tissues. Immunity, 43(2):394–407.
33.
Satoh-TakayamaN, VosshenrichCA, Lesjean-PottierS, SawaS, LochnerM, RattisF, MentionJJ, ThiamK, Cerf-BensussanN, MandelboimO, EberlG, Di SantoJP. 2008. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity, 29(6):958–970.
TuongZK, LewandowskiA, BridgeJA, CruzJL, YamadaM, LambieD, LewandowskiR, SteptoeRJ, LeggattGR, SimpsonF. 2019. Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage. Sci Rep, 9(1):1–11.
37.
van den BrinkMR, AlpdoganO, BoydRL. 2004. Strategies to enhance T-cell reconstitution in immunocompromised patients. Nat Rev Immunol, 4(11):856–867.
38.
van UnenV, HolltT, PezzottiN, LiN, ReindersMJT, EisemannE, KoningF, VilanovaA, LelieveldtBPF. 2017. Visual analysis of mass cytometry data by hierarchical stochastic neighbour embedding reveals rare cell types. Nat Commun, 8(1):1740.
39.
VillanovaF, FlutterB, TosiI, GrysK, SreeneebusH, PereraGK, ChapmanA, SmithCH, Di MeglioP, NestleFO. 2014. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol, 134(4):984–991.
40.
WakitaD, SumidaK, IwakuraY, NishikawaH, OhkuriT, ChamotoK, KitamuraH, NishimuraT. 2010. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol, 40(7):1927–1937.
41.
WangK, KimMK, Di CaroG, WongJ, ShalapourS, WanJ, ZhangW, ZhongZ, Sanchez-LopezE, WuLW, TaniguchiK, FengY, FearonE, GrivennikovSI, KarinM. 2014. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity, 41(6):1052–1063.
42.
WangL, YiT, KortylewskiM, PardollDM, ZengD, YuH. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med, 206(7):1457–1464.
43.
WardNL, UmetsuDT. 2014. A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. J Invest Dermatol, 134(9):2305–2307.
44.
WuL, ChenX, ZhaoJ, MartinB, ZeppJA, KoJS, GuC, CaiG, OuyangW, SenG, StarkGR, SuB, VinesCM, TournierC, HamiltonTA, VidimosA, GastmanB, LiuC, LiX. 2015. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. J Exp Med, 212(10):1571–1587.
ZhaoJ, ChenX, HerjanT, LiX. 2020. The role of interleukin-17 in tumor development and progression. J Exp Med, 217(1):e20190297.
48.
ZhaoY, NiuC, CuiJ. 2018. Gamma-delta (γδ) T cells: friend or foe in cancer development?. J Transl Med, 16(1):3.
49.
ZhuangY, PengLS, ZhaoYL, ShiY, MaoXH, ChenW, PangKC, LiuXF, LiuT, ZhangJY. 2012. CD8+ T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology, 143(4):951–962. e8.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
